Actinium Pharmaceuticals, Inc. (ATNM)
| Market Cap | 206.27M |
| Revenue (ttm) | 888,000 |
| Net Income (ttm) | -22.26M |
| Shares Out | 20.23M |
| EPS (ttm) | -1.27 |
| PE Ratio | n/a |
| Forward PE | 6.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,113,667 |
| Open | 8.98 |
| Previous Close | 8.93 |
| Day's Range | 8.71 - 10.30 |
| 52-Week Range | 5.70 - 13.18 |
| Beta | 1.03 |
| Analysts | Buy |
| Price Target | 32.50 (+236.1%) |
| Est. Earnings Date | Oct 22, 2021 |
About ATNM
Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19 CAR T-cell therapy with memorial sloan kettering cancer center. The company is also developing a mu...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ATNM stock is "Buy." The 12-month stock price forecast is 32.50, which is an increase of 236.09% from the latest price.
News
Actinium Announces Multiple Senior Leadership Appointments Including Chief Business and Commercial Officer, New Chief...
NEW YORK, Sept. 23, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unm...
Actinium to Present at Four Upcoming Investor Conferences
NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unm...
BWXT Medical, Bayer AG Ink Agreement On Actinium-225
Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com Trending
Actinium Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B
NEW YORK, Sept. 15, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that it has completed enrollment of the pivotal Phase 3 SIERR...
Actinium Pharmaceuticals Announces Inclusion in Russell Microcap® Index
NEW YORK, June 28, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced today that it will be added to the Russell Microcap® Index at t...
Actinium Further Strengthens Patent Portfolio with International IP Covering the Composition and Methods of Administr...
NEW YORK, June 17, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that its intellectual property portfolio around its lead Phase...
Actinium's Targeted Radiotherapy Achieves 100% Bone Marrow Transplant Engraftment
Actinium Pharmaceuticals Inc (NYSE: ATNM) highlighted data from its pivotal Phase 3 SIERRA trial evaluating Iomab-B in patients with relapsed or refractory Acute Myeloid Leukemia (AML) aged 55 years and...
Pivotal Phase 3 SIERRA Trial Data Showing 100% Bone Marrow Transplant Engraftment in Patients Treated with Iomab-B pr...
NEW YORK, June 15, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today highlighted data from its pivotal Phase 3 SIERRA trial for Iomab-B in an...
Safety Data Highlighting Low Rates of Adverse Events and Non-Relapse Transplant Related Mortality in Patients Receivi...
NEW YORK, June 15, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today highlighted safety data from its ongoing pivotal Phase 3 SIERRA trial of Iomab-B in patie...
Surging Earnings Estimates Signal Good News for Actinium (ATNM)
Actinium (ATNM) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Actinium Activates Radiation Inside the Body for Target Conditioning of Cancer Cells
Actinium Pharmaceuticals Inc. (NYSE: ATNM), a clinical-stage biopharmaceutical company, is developing antibody radiation-conjugates (ARCs) to combine the targeting ability of antibodies with the cell-ki...
Actinium Announces Several Presentations from the Phase 3 SIERRA Study of Iomab-B at the SNMMI 2021 Virtual Annual Me...
NEW YORK, June 3, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that three abstracts highlighting data and findings from the Co...
7 Reddit Penny Stocks Promising to Cure Cancer
These seven risky Reddit penny stocks are in the biotech space and the business of developing cancer therapies and treatments. The post 7 Reddit Penny Stocks Promising to Cure Cancer appeared first on I...
Actinium to Participate in the Cell & Gene Meeting on the Mediterranean
NEW YORK, March 31, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that it will be participating in the Cell & Gene Meeting on t...
Actinium Announces Completion of Enrollment of Second Dose Cohort in Actimab-A Venetoclax Combination Trial for Patie...
NEW YORK, March 25, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that initial patient enrollment in the second dose cohort in ...
Anthem, Inc. To Acquire myNEXUS, Home Health Benefits Manager
INDIANAPOLIS--(BUSINESS WIRE)--Anthem, Inc. (NYSE: ATNM) today announced that the company has entered into an agreement to acquire myNEXUS, Inc. (“myNEXUS”), a comprehensive home-based nursing managemen...
Actinium Announces Initiation of Patient Enrollment in Iomab-ACT Trial for Targeted Conditioning Prior to CD19 CAR T-...
NEW YORK, March 24, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that its collaborator, Memorial Sloan Kettering Cancer Center...
Actinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next-Generation Actinium-225-Based CD...
NEW YORK, March 11, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that preclinical feasibility data supporting an Actinium-225-...
Actinium Announces Participation in H.C. Wainwright Global Life Sciences Conference
NEW YORK, March 2, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that management will participate in the H.C. Wainwright (HCW) Global Life Scienc...
Actinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting Iomab-B and Pivotal Phase 3 S...
NEW YORK, Feb. 11, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today highlighted its presence at the 2021 Transplantation & Cellular Therapy (...
Actinium Announces Participation in BIO CEO & Investor Digital Conference
NEW YORK, Feb. 10, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that management will participate in the BIO CEO & Investor conf...
Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference
NEW YORK, Jan. 20, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that members of its executive team will participate in a fireside chat at the B....
Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies
NEW YORK, Jan. 13, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced the research collaboration with Astellas Pharma Inc. (TSE:4503) ("Astellas") to ...
Actinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA trial
NEW YORK, Dec. 29, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that the independent Data Monitoring Committee (DMC) has comple...
Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should Know
Actinium Pharmaceuticals (ATNM) closed the most recent trading day at $11.22, moving +0.9% from the previous trading session.